Wang 2017d.

Methods	Study design: Randomised clinical trial Study duration: October 2012 to July 2016 Duration of follow‐up: Not reported Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 55.9 ± 5.72 years, 43‐70 years; TACE: 56.2 ± 5.02 years, 45‐68 years Male (n/total): TACE + RFA: 13/20; TACE alone: 11/20
Interventions	TACE + RFA group (n = 20): TACE: Chemotherapeutic drugs: cisplatin 50 mg, mitomycin 8 mg, and adriamycin 10 mg RFA: The interval between TACE and RFA was 2 weeks. 15‐20 minutes per RFA session TACE group (n = 20): Chemotherapeutic drugs: cisplatin 50 mg, mitomycin 8 mg, and adriamycin 10 mg
Outcomes	Serum level of AFP Tumour response, classified as complete response, partial response, stable disease, and progression
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.